Nathan Bryan Mantlo
Eli Lilly and Company
41 Papers
621 Citations
Nathan Bryan Mantlo is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Peroxisome proliferator-activated receptor & Agonist. The author has an hindex of 19, co-authored 41 publications.
Chat about Author
Papers
Patent
Peroxisome proliferator activated receptor modulators
Scott Eugene Conner,James Allen Knobelsdorf,Nathan Bryan Mantlo,Jeffrey M. Schkeryantz,Shen Quanrong,Warshawsky Alan M,Guoxin Zhu +6 more
- 13 Feb 2003
TL;DR: In this article, a peroxisome proliferator activated receptor (PPAR) was used to treat or prevent disorders mediated by a PPAR such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
123
Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure
Guoqing Cao,Thomas P. Beyer,Youyan Zhang,Robert J. Schmidt,Yan Q. Chen,Sandra L. Cockerham,Karen M. Zimmerman,Sotirios K. Karathanasis,Ellen A. Cannady,Todd Fields,Nathan Bryan Mantlo +10 more
TL;DR: A novel benzazepine compound evacetrapib is described, which is a potent and selective inhibitor of CETP both in vitro and in vivo, and is currently in phase II clinical development.
115
Patent
Compounds and methods for modulating fxr
Michael Gregory Bell,Robert Anthony Doti,Matthew Scott Dowling,Michael James Genin,Peter Ambrose Lander,Tianwei Ma,Nathan Bryan Mantlo,Jason Matthew Ochoada,Lindsay Scott Stelzer,Ryan Edward Stites,Warshawsky Alan M +10 more
- 11 Jul 2008
TL;DR: In this paper, a list of pharmaceutical compositions and methods of use for treating dyslipidemia and diseases related to it is presented. But none of them are described in detail.
78
Patent
Compounds and methods for treating dyslipidemia
Xinchao Chen,Christopher L. Cioffi,Sean Richard Dinn,Ana Maria Escribano,Maria Carmen Fernandez,Todd Fields,Robert Jason Herr,Nathan Bryan Mantlo,De La Nava Eva Maria Martin,Ana Isabel Mateo-Herranz,Saravanan Parthasarathy,Xiaodong Wang +11 more
- 17 Mar 2005
TL;DR: In this paper, the composition and methods of use for treating artherosclerosis and its sequelae were disclosed as useful for treating ARMS and their sequelae, where n, m, p, q, Y, R1 R2, R3, R4, R5, and R6 are defined.
73
Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor α agonist
Yanping Xu,Daniel Ray Mayhugh,Ashraf Saeed,Xiaodong Wang,Richard Craig Thompson,Samuel J. Dominianni,Raymond F. Kauffman,Jaipal Singh,James S. Bean,William R. Bensch,Robert J. Barr,John J. Osborne,Chahrzad Montrose-Rafizadeh,Richard W. Zink,Nathan Yumibe,Naijia Huang,Debra Luffer-Atlas,Deepa Rungta,Dale E. Maise,Nathan Bryan Mantlo +19 more
TL;DR: A new series of hPPARα agonists containing a 2,4dihydro-3H-1,2,4-triazol-3-one core was described leading to the discovery of 5 (LY518674).
71